adeno-associated viral vectors
Regeneron’s Lynozyfic granted FDA accelerated approval to treat multiple myeloma
More than 36,000 new cases of the blood cancer are expected to be diagnosed in the US this year
Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn
The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study
Regeneron to acquire human genetics company 23andMe for $256m
The agreement comes two months after 23andMe filed for bankruptcy protection
Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma
More than 35,000 new cases of the blood cancer are diagnosed every year in Europe
Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer
Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year
Vertex and Orum partner on gene editing conditioning drugs in deal worth $945m
The agreement gives Vertex the rights to use Orum’s targeted protein degradation technology
Regeneron’s odronextamab recommended by CHMP to treat certain lymphomas
Follicular lymphoma and diffuse large B-cell lymphoma are collectively responsible for an estimated 283,000 global cases every year
Scientists discover new form of gene editing to recombine and rearrange DNA
The bridge RNA system allows researchers to edit, delete and convert DNA recombinases without using CRISPR
Regeneron and Mammoth announce gene editing partnership worth $370m per target
The companies will aim to develop CRISPR-based therapies for multiple tissues and cell types
Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol
Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment
Regeneron to acquire 2seventy’s investigational cell therapy pipeline
An estimated 150 2seventy employees will join Regeneron’s new research and development unit
Survey of US oncologists highlights advanced lung cancer research gaps
Non-small cell lung cancer is responsible for approximately 85% of all lung cancers